JB Chemicals & Pharmaceuticals Limited — Q1 FY26 earnings call

Call held 31 Jul 2025

Management summary

J B Chemicals delivered a strong start to FY26, characterized by record operating margins and continued outperformance in the domestic market. While international formulations faced temporary headwinds in Russia and the US, the CDMO segment and chronic domestic portfolio provided robust growth. Management maintained its full-year guidance despite the significant strategic announcement of a controlling stake acquisition by Torrent Pharma.

Highlights

  • Revenue reached ₹1,094 crore, representing a 9% year-on-year growth.

  • Adjusted Operating EBITDA grew 13% to ₹330 crore, excluding ESOP and one-off merger charges.

  • Operating EBITDA margin expanded 120 bps to 30.2%, the highest reported by the company to date.

  • Adjusted PAT (excluding one-offs) stood at ₹214 crore, a 21% increase over the previous year.

  • Domestic business outperformed the industry with 14% growth, reaching ₹678 crore.

  • Gross margins improved by 210 bps to 68.3% due to favorable mix and cost optimization.

  • CDMO business grew 8% to ₹115 crore, with a strong pipeline of 3-4 new launches expected in 12-18 months.

  • Torrent Pharma announced intention to acquire a 46.39% controlling stake from KKR at ₹1,639.18 per share.

Key financials

  1. Revenue ₹1,094 Cr +9%YoY
  2. Operating EBITDA (Adj) ₹330 Cr +13%YoY
  3. EBITDA Margin (Adj) 30.2%
  4. PAT (Adj) ₹214 Cr +21%YoY
  5. Gross Margin 68.3%
  6. R&D Spend 1%

What they filed

Q4 FY26: revenue down 7.2%, net profit down 35.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue952 956 914 901 1,040 +9%1,023 +7%991 +8%836 −7%
EBITDA273 268 245 231 293 +7%298 +11%270 +10%195 −16%
Net profit173 173 156 150 198 +14%200 +16%179 +15%97 −35%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
₹1,094 Cr Total
  • Domestic Business ₹678 Cr 62.0%
  • International Formulations ₹283 Cr 25.9%
  • International CDMO ₹115 Cr 10.5%
  • API Vertical ₹18 Cr 1.6%

Guidance & targets

Revenue

  • Domestic Revenue Growth Alpha Revenue · FY26 · High confidence 12-14%
    we should be in the range of 12% to 14% with 300 bps to 350 bps higher than the market.

    — Kunal Khanna, President Operations

  • CDMO Revenue Growth Revenue · FY26 · High confidence 12-14%
    So CDMO, as we have been guiding earlier, should grow at between 12% to 14%.

    — Nikhil Chopra, CEO

Margin

  • Operating EBITDA Margin Margin · FY26 · High confidence 27-29%
    If you look at the guidance that we had given at the starting of the year was 27% to 29%. So historically see and track us, our guidance, we always want to be at the top percentile of our guidance.

    — Nikhil Chopra, CEO

  • Gross Margin (GC) Margin · FY26 · Medium confidence 67%
    So we hold our guidance where we are looking at the GCs in the range of 67% for the full year

    — Narayan Saraf, CFO

Other

  • Operating Cash Flow Conversion Other · FY26 · High confidence 75-78%
    we clearly expect the yearly cash flow to operating EBITDA in the range of 75% to 78% for the full year '26.

    — Narayan Saraf, CFO

Risks & concerns

  • US Generic Pricing Pressure

    medium

    Management noted slight pricing pressure for two key molecules in the US market, though they expect this to be neutralized in H2.

    Management acknowledged

  • International Market Volatility

    medium

    Russia saw a slow season and South Africa faced muted institutional growth, leading to a 2% decline in international formulations.

    Both acknowledged

  • Merger Integration and Regulatory Approvals

    medium

    Analysts questioned milestones for the Torrent acquisition; management referred only to the press release, citing 'business as usual' internally.

    Analyst deflected

Areas of evasion (2)

  • Specific quarterly run rate for US sales
  • Detailed milestones for the Torrent acquisition/merger process

Q&A highlights

3 direct
Integration Expenses and Merger Costs Direct
Our expenses, which is INR15 crore.

Clarifies the one-time impact of the Torrent merger scheme on the current quarter's profitability.

Asked by Rashmi, Dolat Capital

Domestic Growth Split (Volume vs Price) Direct
So 14% is the domestic growth, price is around 7% and volume is also 7%.

Reveals a healthy, balanced growth profile in the core domestic market rather than reliance on price hikes alone.

Asked by Sumit Gupta, Centrum

Staff Cost Increase Direct
No. So there has been no major expansion in the field force. It's mainly because of the clearly increment and the field incentive that we have provided.

Explains the 16% YoY jump in staff costs as a structural base adjustment rather than temporary expansion.

Asked by Gaurav, Antique

2 min read 5 chapters

Detailed narrative

Strategic Merger with Torrent Pharma

On June 29, Torrent Pharma announced its intention to acquire KKR's 46.39% controlling stake in J B Chemicals for ₹11,917 crore, to be followed by a merger. The transaction triggers a mandatory tender offer at ₹1,639.18 per share. Management emphasized that despite the ownership change, operations remain 'business as usual' with a focus on existing strategic goals. The merger is subject to CCI and other regulatory approvals.

Domestic Market Outperformance

The domestic business grew 14% YoY to ₹678 crore, significantly outperforming the industry's 9% growth. This growth was perfectly balanced with a 7% contribution from price and 7% from volume. The chronic portfolio led the way with 15% growth, while the ophthalmology segment grew 19%. Key brands like Sporlac and Razel crossed significant MAT milestones of ₹146 crore and ₹100 crore, respectively.

CDMO Pipeline and Run-Rate

The CDMO segment grew 8% in Q1 to ₹115 crore, with management guiding for 12-14% growth for the full year. The company has already dispatched first commercial quantities of new products like Iodine Liquid and Throat Spray to Asia Pac and EU markets. Management expects 3 to 4 important new launches in the next 12 to 18 months, with the quarterly run rate expected to rise from ₹120 crore in H1 to ₹130 crore in H2.

International Formulation Headwinds

International formulations revenue declined 2% YoY to ₹283 crore due to a slow season in Russia and muted institutional growth in South Africa. The US market also faced pricing pressure on two key molecules. However, management remains optimistic about a recovery in the second half of the year, citing good order visibility and a pipeline of 8-10 molecules across 14-16 key ROW markets starting in Q4.

Record Margin Profile and Cost Efficiency

J B Chemicals achieved a record operating EBITDA margin of 30.2%, up 120 bps YoY, driven by a 210 bps expansion in gross margins to 68.3%. This was aided by a favorable business mix and consistent cost optimization initiatives. Despite a 16% increase in staff costs due to increments and incentives, the company maintains its full-year EBITDA margin guidance of 27-29%, aiming for the upper end of that range.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls